1. Regidor P-A. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9:34628-38.
2. De Sanctis V, Soliman AT, Daar S, Canatan D, Di Maio S, Kattamis C. Current Issues and Options for Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease: An Update for Health Care Professionals. Mediterranean journal of hematology and infectious diseases. 2020;12:13-1.
3. Jacobstein R, Polis CB. Progestin-only contraception: Injectables and implants. Best Pract Res Clin Obstet Gynaecol. 2014;28:795-806.
4. Ma Z, Zhang H, Wang Y, Tang X. Development and evaluation of intramuscularly administered nano/microcrystal suspension. Expert Opin Drug Deliv. 2019;16:347-61.
5. Bruni V, Dei M, Pampaloni F. Hormonal contraception. Female Reproductive Dysfunction. 2020:123-52.
6. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43-52.
7. Rocca ML, Palumbo AR, Visconti F, Di Carlo C. Safety and benefits of contraceptives implants: A systematic review. Pharmaceuticals (Basel, Switzerland). 2021;14:548.
8. Moray KV, Chaurasia H, Sachin O, Joshi B. A Systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health. 2021;18:1-24.
9. Powell A. Choosing the right oral contraceptive pill for teens. Pediatr Clin North Am. 2017;64:343-58.
10. Ingle S, Tegeli V, Javalgikar A, Matole V, Koli L, Birajdar A, et al. A Brief review on intra-uterine drug delivery systems. RJPDFT. 2021;13:72-5.
11. Bao Q, Gu B, Price CF, Zou Y, Wang Y, Kozak D, et al. Manufacturing and characterization of long-acting levonorgestrel intrauterine systems. International journal of pharmaceutics. 2018;550:447-54.
12. Boog K, Cooper M. Long acting reversible contraception. Obstet Gynaecol Reprod Med 2021;31:185-91.
13. Sergison JE, Maldonado LY, Gao X, Hubacher D. Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis. American journal of obstetrics and gynecology. 2019;220:440-8.e8.
14. Regidor P-A. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9:34628-38.
15. Buckner LR, Drobnis EZ, Augustine MS, Rogers LK, Akers J, Mott PD, et al. Cervical and systemic concentrations of long acting hormonal contraceptive (LARC) progestins depend on delivery method: Implications for the study of HIV transmission. PLoS One. 2019;14:e0214152.
16. Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9:34628-38.
17. Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson ED. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception. 1990;42:51-66.
18. Yang Z, Shao L, Teng Y. Evaluation of the Efficacy and Adverse Reactions of Mirena Combined with Hysteroscopic Surgery When Treating AUB: Based on a Retrospective Cohort Study. Computational and Mathematical Methods in Medicine. 2022;2022:4082266.
19. Sergison JE, Maldonado LY, Gao X, Hubacher D. Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis. Am J Obstet Gynecol. 2019;220:440-8.
20. Sadeghi-Bazargani H, Fardyazar Z. Amenorrhea: an advantage rather than a complication of Depot medroxy progesterone acetate injection contraceptive. International Journal of Pharmacology. 2006;2:352-56.
21. Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9:34628-38.
22. Wong RC, Bell RJ, Thunuguntla K, McNamee K, Vollenhoven B. Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users. Contraception. 2009;80:452-6.
23. Teal SB, Sheeder J. IUD use in adolescent mothers: retention, failure and reasons for discontinuation. Contraception. 2012;85:270-4.
24. Howard DL, Wayman R, Strickland JL. Satisfaction with and intention to continue Depo-Provera versus the Mirena IUD among post-partum adolescents through 12 months of follow-up. J Pediatr Adolesc Gynecol. 2013;26:358-65.
25. Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76:267-72.
26. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117:1105-13.